Philip Morris International Inc. (PMI) announced an updated financial outlook during a presentation at the Barclays Global Consumer Conference on September 8, 2026. The company raised its forecast for adjusted diluted earnings per share (EPS) for the full year 2026.
The new guidance projects adjusted diluted EPS of $8.35 to $8.50, representing growth of 10.7% to 12.7% compared to the prior year. This increase includes a favorable currency impact of 24 cents per share. For the third quarter of 2026, the company anticipates adjusted diluted EPS of $2.29 to $2.34.
The presentation highlighted the continued performance of the IQOS system, noting that consumer offtake in Japan is recovering as expected, with pricing confirmed for October. International markets are seeing strong multicategory growth, driven by products such as VEEV and ZYN. In the United States, PMI is expanding the ZYN range and aligning the value proposition across the portfolio, specifically transitioning 3mg and 6mg dry variants to 20 pouches per can in the fourth quarter.
The company also disclosed specific adjustments included in the EPS calculation, such as a $0.10 charge related to Germany excise tax classification litigation, a $0.10 benefit from the RBH (Canada) Plan Implementation, and a $0.09 impairment related to an equity investment in the Wellness business.
